Is is time to sell Aurora Cannabis (TSX:ACB)?
Roth Capital Partners analyst Bill Kirk reiterated a "Neutral" rating on Aurora Cannabis (TSX:ACB) but lowered his price target to $4.00 from $5.00 due to a larger-than-expected drag from Canadian medical cannabis reimbursement changes. While Aurora benefits from its international opportunities and EU-GMP infrastructure, …